AstraZeneca (AZ) and Amgen have shared positive results from a late-stage study of Tezspire (tezepelumab) in patients with ...
Daiichi Sankyo has entered into an exclusive licence agreement worth up to $300m with Alteogen to develop a subcutaneous ...